Recent Updates
Recently added Catalysts
BLTE Positive Sentiment

Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1

Tuesday, August 11, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Belite Bio has announced that the FDA has accepted its New Drug Application for tinlarebant, which is under priority review. If approved, tinlarebant will be the first-ever treatment for Stargardt Disease Type 1. The Prescription Drug User Fee Act target action date is set for February 12, 2027.

Market Sentiment Analysis

POSITIVE FACTORS

  • FDA acceptance of the New Drug Application for tinlarebant.
  • Priority review status could expedite the approval process.
  • Potential to be the first approved treatment for Stargardt Disease Type 1.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+32%
120-day peak, hindsight
Typical move
6.1%
average across 7 past catalysts
Lead asset
Tinlarebant
Phase 3 · Geographic Atrophy

Full Press Release Details

Prescription Drug User Fee Act target action date is February 12, 2027 If approved, tinlarebant would be the first-ever approved treatment for Stargardt Disease Type 1 SAN DIEGO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage

Frequently Asked Questions

What is tinlarebant used for?

Tinlarebant is being developed for the treatment of Stargardt Disease Type 1.

What is the FDA's target action date for tinlarebant?

The FDA's target action date for tinlarebant is February 12, 2027.

What does priority review mean?

Priority review means the FDA will expedite the review process for tinlarebant.

Is tinlarebant the first treatment for Stargardt Disease?

Yes, if approved, it would be the first-ever treatment for Stargardt Disease Type 1.

ShareAdd on Google
Tags: BLTE Viatris Investor Conferences Healthcare Belite Bio tinlarebant Stargardt Disease FDA acceptance clinical-stage
Last updated: Aug 11, 2026

Biotech snapshot

Lead asset
TinlarebantPhase 3
Geographic Atrophy →

Catalyst track record

+32%
best trade around BLTE's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for BLTE.

See every catalyst's timing & PoA →